Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated musle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.
Type:
Grant
Filed:
April 15, 2021
Date of Patent:
July 23, 2024
Assignee:
Acceleron Pharma Inc.
Inventors:
Ravindra Kumar, Jonathan Belk, Asya Grinberg, Dianne Sako, Roselyne Castonguay
Abstract: The disclosure features methods for treating solid tumor malignancies and lymphomas by administering LNP encapsulated mRNAs encoding human OX40L, IL-23 and IL-36? polypeptides alone or in combination with checkpoint blockade. The disclosure also features compositions for use in the methods.
Abstract: The present invention generally relates to diagnostic assays using cell cultures, in particular to chimeric antigen receptor (CAR) expressing reporter cell assays to analyze samples, in particular patient samples, to diagnose cancer by quantifying the expression of tumor antigens and/or predicting clinical response to cancer immunotherapies. A further aspect of the present invention is to improve safety of e.g., cancer immunotherapies.
Type:
Grant
Filed:
October 2, 2020
Date of Patent:
July 16, 2024
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Diana Darowski, Camille Loise Sophie Delon, Lydia Jasmin Hanisch, Christian Jost, Christian Klein, Ekkehard Moessner, Vesna Pulko, Wei Xu
Abstract: A biological catalyst for the regeneration of tissues, obtainable directly from an adipose starting material, includes adipose material in liquid solution in a quantity of between 1.0 and 1.5 grams per millilitre of adipose starting material, in which a quantity of between 2 and 30 milligrams of proteins is present, said proteins comprising at least: from 0 to 60 picograms of PDGF, from 300 to 1300 picograms of VEGF, from 10 to 100 picograms of TGFb1, from 3000 to 7500 picograms of FGFb, from 400 to 4000 picograms of IL-1 RA. The biological catalyst is obtained from a method including at least the steps of collecting an adipose starting material; centrifuging the adipose material, to separate the collected material at least into an oily fraction, an aqueous fraction and a cellular fraction; removing the surface oily fraction; collecting the aqueous fraction and the cellular fraction, in which the above-mentioned proteins are found.
Abstract: Provided herein, are methods of identifying neoantigens for treating and preventing cancer. Also disclosed are methods and compositions for administering identified neoantigens for the treatment and prevention of cancer.
Type:
Grant
Filed:
April 1, 2022
Date of Patent:
June 25, 2024
Assignee:
Arizona Board of Regents on Behalf of Arizona State University
Abstract: This technology describes novel cell based combined therapeutic modalities that induces mechanism based tumor cell killing in a broad spectrum of sensitive and resistant tumors. These new agents are tumor specific and target a broad spectrum of solid tumors.
Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
Type:
Grant
Filed:
February 2, 2021
Date of Patent:
May 28, 2024
Inventors:
Thomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, William M. Keefe, Nick Knudsen, Lillian Skidmore, Jason Pinkstaff, Vadim Kraynov
Abstract: The present disclosure is generally directed to Siglec-9 ECDs and Siglec-9 ECD fusion molecules, and methods of treatment using Siglec-9 ECDs and Siglec-9 ECD fusion molecules.
Abstract: The disclosure provides antibody molecules that bind to TCR V? regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
Type:
Grant
Filed:
August 18, 2022
Date of Patent:
April 23, 2024
Assignee:
Marengo Therapeutics, Inc.
Inventors:
Seng-Lai Tan, Brian Edward Vash, Jonathan Hsu, Dilini Charmain Gunasekera, Sangeetha Sagar Palakurthi, Andreas Loew
Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to CXCR5. The antibodies can be afucosylated and exhibit increased ADCC compared with the otherwise identical fucosylated antibodies. The invention includes uses, and associated methods of using the antibodies.
Type:
Grant
Filed:
November 20, 2020
Date of Patent:
April 16, 2024
Assignees:
Pfizer Inc., The Regents of the University of California
Inventors:
Rachel Groth, William Brian Snyder, Xianjun Cao, Robert Joseph Dunn, Joseph Dal Porto, Michael Karin
Abstract: The subject matter disclosed herein is generally directed to modulating T cell dysfunctional and effector states by modulating glucocorticoid and IL-27 signaling. The invention further relates to modulating immune states, such as CD8 T cell immune states, in vivo, ex vivo and in vitro. The invention further relates to diagnostic and screening methods.
Type:
Grant
Filed:
April 26, 2019
Date of Patent:
April 16, 2024
Assignees:
The Broad Institute, Inc., Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
Inventors:
Ana Carrizosa Anderson, Asaf Madi, Nandini Acharya, Vijay K. Kuchroo, Aviv Regev
Abstract: Bioconjugates and methods of making bioconjugates are provided, wherein the bioconjugates comprise glucose oxidase and nanoparticles that can kill tumor cells. For example, glucose oxidase-iron oxide bioconjugates can produce reactive oxygen species from blood glucose, causing cell death. The use of superparamagnetic iron oxide nanoparticles can provide magnetic resonance imaging guidance to facilitate imaging-guided drug delivery and combine diagnostics with therapy.
Type:
Grant
Filed:
November 21, 2019
Date of Patent:
March 19, 2024
Assignee:
UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Abstract: Methods are provided for producing a PEGylated interleukin 11 (IL-11) by treating a recombinant IL-11 PEGylated with an equimolar to low molar excess of PEG carrying an amine-reactive group to achieve a highly pure monoconjugate preparation, which provides improved half-life in serum while having desirable therapeutic activity and presenting fewer side-effects. Most preferably, the IL-11 is an N-terminally truncated human or humanized IL-11 and has a 20 Kd or 40 Kd branched PEG moiety, Y- or comb-shaped in particular, coupled to the N-terminal amino group. Such compounds are characterized by substantially increased stability in serum and sustained biological activity while exhibiting significantly reduced plasma expansion.
Type:
Grant
Filed:
February 11, 2021
Date of Patent:
March 19, 2024
Assignee:
Nansha Biologics (Hong Kong) Limited
Inventors:
Kuo-Ming Yu, Qui-Lim Choo, Manson Fok, Johnson Yiu-Nam Lau
Abstract: Methods and compositions for treating cancer, e.g., prostate cancer, using a combination of P-Rex1 or Rac1 inhibitors and VEGF/VEGFR-targeted therapy.
Abstract: Antibodies and antigen binding fragments thereof that immunospecifically bind OPN (OPN) and inhibit OPN activity are provided herein. The disclosed antibodies and antigen binding fragments are useful for modulating signal transduction through OPN proteins. The antibodies and antigen-binding fragments are useful for the treatment or prevention of cancer, osteoporosis, or other immune diseases.
Type:
Grant
Filed:
December 4, 2020
Date of Patent:
February 13, 2024
Assignees:
Augusta University Research Institute, Inc., Department of Veterans Affairs
Inventors:
Kebin Liu, John Klement, Priscilla S. Redd
Abstract: Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2R? (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer.
Type:
Grant
Filed:
October 20, 2021
Date of Patent:
February 13, 2024
Assignee:
GILEAD SCIENCES, INC.
Inventors:
Manuel Baca, Sarah A. Gilmore, Hassan Javanbakht, Prasenjit K. Mukherjee
Abstract: The present invention relates to gamma delta (??) T cells and/or Natural Killer (NK) cells expressing constructs to provide for the expression of a Chimeric Antigen Receptor (CAR) incorporating the signalling domain of FCY Receptors. Suitably the invention also relates to constructs to provide such CARs and methods for introducing such CARs into cells and expressing such CARs in cells comprising receptors of gamma delta (??) T cells and/or Natural Killer (NK) cells.
Abstract: A machine-learning model (e.g., a clustering model) may be used to predict a phenotype of a tumor based on expression levels of a set of genes. The set of genes may have been identified using a same or different machine-learning model. The phenotype may include an immune-excluded, immune-desert or an inflamed/infiltrated phenotype. A treatment strategy and/or treatment recommendation may be identified based on the predicted phenotype.